ZOLL TherOx SuperSaturated Oxygen Therapy to be Highlighted at TCT Scientific Symposium

CONTACT:

Matt Hogan

ZOLL Medical Corporation

ZOLL THEROX SUPERSATURATED OXYGEN THERAPY TO BE HIGHLIGHTED AT TCT SCIENTIFIC SYMPOSIUM

November 4, 2021 — CHELMSFORD, MASS. — ZOLL^® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx^® SuperSaturated Oxygen (SSO₂) Therapy will be highlighted at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific meeting November 4-6 in Orlando, Florida. The TCT Scientific Meeting, the world's premier conference for interventional cardiovascular medicine, will offer both live and virtual options for the 2021 meeting.

ZOLL TherOx will host product demonstrations and discussions with thought leaders who will share their real-world experiences with SSO₂ Therapy in technology suite #CS 5.

In addition, Stephen Lynch, MD (Beaumont Hospital, MI) will be presenting a case study featuring SSO₂ Therapy and one patient's remarkable recovery during the Moderated Challenging Case session TCT 517 on November 6 at 1 p.m. EDT in Halls A-B, Level 1.

"Our participation in and support of TCT is an essential part of expanding the frontier of STEMI care with SSO₂ Therapy," said Neil Johnston, President of ZOLL Circulation.

SuperSaturated Oxygen (SSO₂) Therapy is the first and only FDA-approved treatment shown to significantly reduce myocardial damage in heart attack patients after percutaneous coronary intervention. SSO₂ Therapy delivers dissolved oxygen at 7-10x normal directly to the damaged heart muscle to salvage heart tissue immediately after the coronary artery has been successfully opened via angioplasty and stenting. In clinical studies it has been shown to reduce infarct size by 26% in patients who suffer left anterior descending ST-elevation myocardial infarction (LAD STEMI) – also known as widowmaker heart attacks due to the high mortality rate – and are treated within six hours of symptom onset.¹

SSO₂ Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL.

About ZOLL Medical Corporation

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 40,000 employees around the world, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.

¹ Stone, G.W. et al. Circ Cardiovasc Interv; 2; 366-375. Sep 2009.

Copyright © 2021 ZOLL Medical Corporation. TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.

###